Abstract
The most common cancer for women in the United Kingdom is breast cancer and it is well known that genomic modifications are responsible for breast carcinogenesis. Major developments in genomics and proteomics have uncovered biomarkers which have a crucial role in this process. To move towards individualized and improved breast cancer care, there is a need for tumor markers that are associated with disease diagnosis, prognosis, treatment and monitoring. General opinion is that biomarkers can bring more accurate and sensitive tools to the clinical settings than conventional approved histopathological parameters. However, clinical applications of breast tumor markers remain quite low in numbers because the data regarding these novel markers for breast cancer is limited and do not allow well-grounded conclusions. This review presents a non exhaustive selection of biomarkers published, some validated, and their uses in breast cancer management.
Keywords: Breast cancer, tumor markers, diagnosis, prognosis, therapy, NPI
Current Cancer Therapy Reviews
Title: Emerging Breast Cancer Biomarkers
Volume: 4 Issue: 2
Author(s): Stephanie A. Laversin, Amanda K. Miles, Graham R. Ball and Robert C. Rees
Affiliation:
Keywords: Breast cancer, tumor markers, diagnosis, prognosis, therapy, NPI
Abstract: The most common cancer for women in the United Kingdom is breast cancer and it is well known that genomic modifications are responsible for breast carcinogenesis. Major developments in genomics and proteomics have uncovered biomarkers which have a crucial role in this process. To move towards individualized and improved breast cancer care, there is a need for tumor markers that are associated with disease diagnosis, prognosis, treatment and monitoring. General opinion is that biomarkers can bring more accurate and sensitive tools to the clinical settings than conventional approved histopathological parameters. However, clinical applications of breast tumor markers remain quite low in numbers because the data regarding these novel markers for breast cancer is limited and do not allow well-grounded conclusions. This review presents a non exhaustive selection of biomarkers published, some validated, and their uses in breast cancer management.
Export Options
About this article
Cite this article as:
Laversin A. Stephanie, Miles K. Amanda, Ball R. Graham and Rees C. Robert, Emerging Breast Cancer Biomarkers, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310179
DOI https://dx.doi.org/10.2174/157339408784310179 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews ANN Classification and Modified Otsu Labeling on Retinal Blood Vessels
Current Signal Transduction Therapy The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry Application of Diet-derived Taste Active Components for Clinical Nutrition: Perspectives from Ancient AyurvedicMedical Science, Space Medicine, and Modern Clinical Nutrition
Current Pharmaceutical Design Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA
Current Cancer Therapy Reviews Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) A Systematic Review of Meta-Analyses on Gene Polymorphisms and Gastric Cancer Risk
Current Genomics Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety ‘Treat to Target’ in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy
Current Drug Targets Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology
Current Molecular Medicine Determination of Binding Potency of Peptidic Inhibitors of Grb2-SH2 by Using the Protein-Captured Biosensor Method
Protein & Peptide Letters Using Microgravity for Defining Novel Anti-Atherosclerotic Therapy
Current Genomics Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis
Current Drug Targets Preface - Special Issue “Mini-Reviews in Medicinal Chemistry” Proceedings of the Twentieth Anniversary of the Faculty of Pharmacy of the University of Calabria
Mini-Reviews in Medicinal Chemistry Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Walking a Tightrope: A Perspective of Resveratrol Effects on Breast Cancer
Current Protein & Peptide Science <sup>68</sup>Ga-labeled HBED-CC Variant of uPAR Targeting Peptide AE105 Compared with <sup>68</sup>Ga-NODAGA-AE105
Anti-Cancer Agents in Medicinal Chemistry